Ann: Circulation Publishes Improved Outcomes with Mesoblast Cells, page-4

Of course Moreforme. I'm just saying the questions I raised touch on some "confused face" issues.
The stats appear very good yet earlier it says 'potential efficacy?" just odd as those 2 things are opposites to each other.

And the low dose component is POV but I wonder why they didn't just go with the heavy dose like what has proven effective for them in the past.
Guess they were curious about low dose.

My only issue with a low dose is I'd just prefer them to stick to what they know works and shows very compelling results. After we get to market they can explore interesting things.
Right now its all about just getting the green light so the company can power on and I'd rather they not flirt with low doses which given their previous reports were never as compelling as when they used high doses.